Takeda Pharmaceutical Co.
 |
|
|
Native name
|
武田薬品工業株式会社 |
|---|---|
| Public KK | |
| Traded as |
|
| Industry | Pharmaceuticals |
| Founded | Doshomachi, Osaka, Japan (June 12, 1781) |
| Headquarters | 1-1, Doshomachi Yonchome, Chuo-ku, Osaka, Japan |
|
Key people
|
Yasuchika Hasegawa (Chairman of the Board) Christophe Weber (President & CEO) |
| Revenue |
 ¥1,557,267 million (FY 2012) |
 ¥122,505 million (FY 2012) |
|
|
¥131,244 million (FY 2012) |
|
| Total assets |
¥3,955,599 million (FY 2012) |
| Total equity |
¥2,223,359 million (FY 2012) |
|
Number of employees
|
30,481 (2012) |
| Website |
takeda |
|
Footnotes / references |
|
Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha?) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company in the world. The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Millennium: The Takeda Oncology Company. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.
Takeda Pharmaceuticals was founded on June 12, 1781, and was incorporated on January 29, 1925.
In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launched the blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.
One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. Launched in 1999, Actos has become the best-selling diabetes drug in the world with 4 billion USD in sales during the 2008 fiscal year.
...
Wikipedia